Talazoparib trial moves a targeted prostate cancer drug to an earlier stage

Overview

Updated Jul 30

About one in four men with advanced prostate cancer carry inherited flaws in the genes that repair damaged DNA. A large trial now shows that giving those men a targeted pill alongside standard hormone therapy delays the cancer's spread by a wide margin.

The New England Journal of Medicine published the final TALAPRO-3 results on July 30, 2026. The data support a pending U.S. approval that would push the drug into an earlier, more treatable stage of the disease.

Why it matters

For the roughly one in four advanced prostate cancer patients with these DNA-repair mutations, adding one pill more than halved the risk of the cancer spreading.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

52%

Lower risk of progression or death

Adding talazoparib cut the risk of the cancer growing or the patient dying, versus hormone therapy alone.

599

Patients enrolled

Men with metastatic castration-sensitive prostate cancer carrying HRR gene mutations.

75%

Objective response rate

Share whose tumors shrank on the combination, versus 67% on hormone therapy alone.

51%

Severe anemia

Grade 3 or higher anemia in the talazoparib group, mostly managed by lowering the dose.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Neeraj Agarwal

Global lead investigator, TALAPRO-3

Presented the final results at ASCO 2026

Andrew Armstrong

Prostate cancer researcher and trial commentator

Public discussant of the TALAPRO-3 data

Organizations Involved

Pfizer Inc.

Pharmaceutical company

Maker of both drugs; sponsor of the FDA application

Pfizer sells talazoparib (Talzenna) and co-markets enzalutamide (Xtandi), and is seeking to expand the pair into earlier prostate cancer.

U.S. Food and Drug Administration

Federal regulatory agency

Reviewing the expanded use under priority review

The FDA reviews and approves new drug uses in the United States and is deciding whether to clear the combination for earlier-stage prostate cancer.

Timeline

June 2023 July 2026

4 events Latest: July 30th, 2026 · 1 month ago

Tap a bar to jump to that date

July 2026
Final results published in the New England Journal of Medicine
Latest Publication

The NEJM publishes the full TALAPRO-3 dataset, cementing the evidence behind the pending FDA review of the combination.
July 30th, 2026
FDA grants priority review
Regulatory

The FDA accepts Pfizer's application to expand the combination into castration-sensitive disease and sets a decision date in late 2026.
July 13th, 2026
May 2026
TALAPRO-3 results unveiled at ASCO
Clinical Data

Investigators report a 52% reduction in the risk of progression or death, with benefit in both BRCA and non-BRCA patients. Data were released alongside a journal publication.
May 30th, 2026
June 2023
Combination approved for later-stage prostate cancer
Regulatory

The FDA clears talazoparib plus enzalutamide for HRR-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial.
June 20th, 2023

Scenarios

FDA approves the combination for earlier-stage prostate cancer

Likely Resolves by Q1 2027

Discussed by: Pfizer; oncology trade press including Urology Times and CancerNetwork

The FDA clears talazoparib plus enzalutamide for HRR-mutated castration-sensitive prostate cancer on or near its late-2026 target date. Priority review status and a strong progression benefit point this way, though the agency could still narrow the label. Approval would let oncologists start the drug one stage earlier, when the cancer is more treatable.

FDA narrows the approval to BRCA-mutated patients only

Possible Resolves by Q1 2027

Discussed by: Oncology analysts noting the agency's earlier PARP inhibitor decisions

The FDA approves the combination but limits it to men with BRCA mutations, a subset of the broader HRR group. The trial showed a stronger effect in BRCA patients (hazard ratio 0.37) than non-BRCA patients (0.57), and the agency has restricted rival PARP combinations this way before. A narrow label would shrink the eligible population.

Mature data show men live longer, not just progress slower

Uncertain Resolves by End of 2028

Discussed by: Andrew Armstrong and other trial commentators tracking overall survival

Follow-up confirms a statistically significant overall survival benefit, the endpoint that matters most to patients. Early data trended in the drug's favor, with fewer deaths in the treatment group, but the survival analysis was not yet mature at publication. A confirmed benefit would settle the central open question about the combination.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 1998

Trastuzumab and the biomarker-drug model (1998)

The FDA approved trastuzumab for breast cancers that overexpress the HER2 protein, paired with a companion test. It tied a drug's use to a specific genetic feature of the tumor for the first time at scale.

Then

HER2 testing became standard, sorting patients into those likely to benefit and those unlikely to.

Now

It set the template for precision oncology: test first, then treat the matched subgroup.

Why this matters now

TALAPRO-3 follows that model, giving the drug only to men whose tumors carry the targeted DNA-repair mutations.

May 2020

First PARP inhibitor approved in prostate cancer (2020)

The FDA approved olaparib for men with HRR-mutated metastatic castration-resistant prostate cancer, based on the PROfound trial. It was the first time a PARP inhibitor, a drug class born in ovarian and breast cancer, reached prostate cancer patients.

Then

Genetic testing for BRCA and related mutations became routine in advanced prostate cancer.

Now

It opened the door to PARP inhibitor combinations that later moved the class earlier in treatment.

Why this matters now

TALAPRO-3 continues that push, testing whether the same biology helps men at an earlier, hormone-sensitive stage.

2023

PARP-plus-hormone combinations reach castration-resistant disease (2023)

The FDA approved three PARP inhibitor and hormone-therapy combinations for castration-resistant prostate cancer, including talazoparib with enzalutamide. But it restricted some of them to BRCA-mutated patients rather than the full HRR group.

Then

Oncologists gained new options but had to match each drug to a specific mutation profile.

Now

The BRCA-versus-HRR labeling debate became the central regulatory question for the class.

Why this matters now

It shows why a TALAPRO-3 approval could still come with a narrower label than the trial population.